Corona Remedies Limited IPO Review
Neutral1008-1062 · Mainboard
✦
Analyst Verdict
Corona Remedies Limited IPO
Neutral
IPO at a Glance
Price Band
1008-1062
Issue Size
655cr
Min. Investment
₹14,868
Opens
2025-12-06
Closes
2025-12-08
Listing
2025-12-13
Category
Mainboard
Key Strengths
✓Consistent revenue growth with a CAGR of approximately 21% over the last three years.
✓Diversified product portfolio across multiple therapeutic areas.
✓Strong distribution network with a presence in urban and semi-urban areas.
✓Leadership positions in specific therapeutic segments, such as women’s healthcare and pain management.
✓EU-GMP and WHO-certified manufacturing facilities ensure high-quality production standards
Key Risks
⚠High working capital intensity with a gross operating cycle exceeding 150 days.
⚠Exposure to regulatory risks inherent in the pharmaceutical industry.
⚠Dependence on contract manufacturing for certain products.
⚠Ongoing capital expenditure projects with associated completion and cost risks.
⚠Presence in a competitive and price-controlled domestic pharmaceutical market.
Frequently Asked Questions
Should I apply for Corona Remedies Limited IPO?
Based on our analysis, our rating for Corona Remedies Limited IPO is: Neutral. Review the full analysis including strengths, risks, and financials on CheckIPO before making a decision.
What are the key risks of Corona Remedies Limited IPO?
High working capital intensity with a gross operating cycle exceeding 150 days. Exposure to regulatory risks inherent in the pharmaceutical industry. Dependence on contract manufacturing for certain products.
What are the strengths of Corona Remedies Limited IPO?
Consistent revenue growth with a CAGR of approximately 21% over the last three years. Diversified product portfolio across multiple therapeutic areas. Strong distribution network with a presence in urban and semi-urban areas.
What is the price band of Corona Remedies Limited IPO?
The price band for Corona Remedies Limited IPO is 1008-1062. The IPO has closed.
Full Analysis Available
Financials, DRHP breakdown, peer comparison, shareholding pattern & more